key: cord-0686120-gxua055k authors: Güven, Mehmet; Gültekin, Hamza title: The prognostic impact of thyroid disorders on the clinical severity of COVID‐19: Results of single‐centre pandemic hospital date: 2021-03-13 journal: Int J Clin Pract DOI: 10.1111/ijcp.14129 sha: 166e7d6874eb6e29d0e059257cd2f696481d127c doc_id: 686120 cord_uid: gxua055k BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection can cause thyroid hormonal disorders. In addition, tracheal compression by thyroid nodules can aggravate hypoxia in critically ill patients. No studies have investigated the effect of thyroid nodules on the prognosis of patients with COVID‐19. In this study, we investigated the effect of thyroid hormonal disorders and thyroid nodules on the prognosis of patients with COVID‐19. MATERIALS AND METHODS: This prospective study was conducted at the Şırnak State Hospital (Pandemic hospital in Turkey) between 15 March and 15 August 2020. We evaluated thyroid hormonal disorder and thyroid nodules in 125 patients who were admitted to the non‐intensive care unit (non‐ICU) due to mild COVID‐19 pneumonia (group 1) and 125 critically ill patients who were admitted to the ICU (group 2). RESULTS: Thyroid‐stimulating hormone levels (TSH) were not significantly different between groups 1 and 2; however, group 2 patients had significantly lower levels of free thyroxine (FT4) and free triiodothyronine (FT3) as compared to group 1 (P = .005, P < .0001, respectively). FT3 level showed a negative correlation with length of hospital stay and C‐reactive protein level (rho: −0.216, p: 0.001; rho: −0.383, P < .0001). Overt thyroid disorder was observed in 13 patients [2 patients in group 1 (both with overt thyrotoxicosis) and 11 patients in group 2 (3 overt hypothyroidism, 8 overt thyrotoxicosis) (P = .01)]. Thyroid nodules sized ≥1 cm were found in 9 patients (7%) in group 1 and 32 patients (26%) in group 2 (P < .0001). CONCLUSION: Overt thyroid hormonal disorders were more common in critically ill COVID‐19 patients. FT3 level at hospital admission is a potential prognostic marker of COVID‐19 patients. Thyroid nodules may be associated with severe COVID‐19 disease. hospital in Turkey) due to mild COVID-19 pneumonia and 125 critically ill patients admitted to the ICU due to COVID-19 pneumonia (dyspnea, hypoxia, respiratory failure, shock, or multiorgan dysfunction) were included in the study. Patients with mild symptoms in the non-ICU were categorised as group 1, while patients with the critical condition in the ICU were categorised as group 2. Patients in the ICU were further divided into two subgroups, survivour (n = 88) and deceased (n = 37). Length of hospital stay was defined as the interval between the first hospitalisation and the day of discharge from the hospital. This prospective study was approved by the Health Sciences Ethics Committee (decision no. 2020/546, Diyarbakır, Turkey). The diagnosis of COVID-19 was based on positive results of realtime reverse-transcriptase polymerase chain reaction (RT-PCR) test of nasopharyngeal and oropharyngeal swabs or the presence of strong clinical and radiological signs of COVID-19 even if the nasopharyngeal swab result was negative. In Group 1, fasting blood samples of patients were obtained at 07.00-08.00 hours on the first morning of their hospitalisation. Complete blood count, glucose, urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, ferritin, C-reactive protein (CRP), D-dimer, thyroid-stimulating hormone (TSH), free T4 (FT4), free T3 (FT3), antithyroid peroxidase (Anti-TPO), anti-thyroglobulin (Anti-Tg) levels were measured. In group 2, blood samples for the above-mentioned investigations were obtained at 07.00-08.00 hours on the first morning of their admission to the ICU. Hormone levels were analysed using the Cobas 6000 analyser (Roche Diagnostics, Germany). Thyroid hormone results obtained from patients were classified according to the definitions given below. Overt thyrotoxicosis was defined as low TSH level and serum FT3 and/or FT4 above the respective reference range. Overt hypothyroidism was defined as high TSH level and serum FT4 and/or FT3 below the respective reference range. Subclinical thyroid dysfunction was defined as the presence of low or high TSH levels accompanied by FT4 and FT3 within the respective reference range. • With this study, it was revealed that thyroid hormones are affected by COVID-19 in the intensive care unit. • In addition, thyroid nodules have been shown for the first time to be a poor prognostic factor for COVID-19. Non-thyroidal illness syndrome (NTIS) was defined as the presence of normal serum TSH, normal or high FT4, low FT3 or low serum TSH, FT4, FT3. Other pituitary hormone levels (prolactin, ACTH, cortisol,FSH and LH) were assessed to differentiate NTIS from central hypothyroidism. A distinction was made from central hypothyroidism as the other pituitary hormone levels were found to be normal or high. Thyroid ultrasonography to assess the presence of subacute thyroiditis was performed in all patients with thyrotoxicosis. All thoracic CT studies were performed using a 16-slice CT scanner (Alexion 16, Toshiba Medical Systems, Japan). The acquisition parameters included detector row configurations of 0.625 mm and section thicknesses of 3 mm. Iodine contrast agents were not used for chest CT imaging. Non-contrast chest CT images with suspicion of pneumonia were examined. Thyroid gland was examined in chest CT cervical sections. Patients with incidentally detected nodule ≥1 cm in the thyroid gland were classified as "nodule positive." Figure 1 shows a representative non-contrast chest CT image of a patient in group 2 showing a nodule in the thyroid gland. Patients with previously known pituitary disorder, thyroid disorder, diabetes mellitus, kidney and liver disease were excluded. Because we investigated newly developed thyroid hormone disorders due to COVID-19. Also, patients using drugs such as thyroid hormone therapy (levothyroxine or antithyroid drug), amiodarone, dopamine, dobutamine, corticosteroid, furosemide, nonsteroidal anti-inflammatory drugs (NSAIDs), heparin, anticonvulsants, metformin, or immunotherapy that could disrupt thyroid tests were excluded from the study. In addition, who were pregnant were excluded from the study. Apart from this, all patients over the age of 18 were included in the study. Statistical analysis was performed using the SPSS (Statistical Package for Social Sciences) for Windows 18.0 programme. Categorical variables are presented as frequency (percentage), while continuous variables are presented as median (interquartile range). Between-group differences with respect to categorical variables were assessed using the Chi-squared test, while those with respect to nonparametric continuous variables were assessed using the Mann-Whitney test. Spearman's correlation test was used to assess the correlation between two variables. P values < .05 were considered indicative of statistical significance. The median glucose level in groups 1 and 2 was 110 (IQR, 93-128) mg/dL and 139 (IQR, 113.5-189.5) mg/dL, respectively (P < .0001). Thyroid nodules seen on non-contrast chest CT cervical sections (arrow) The median CRP level in groups 1 and 2 was 1.88 (IQR, 0.51-4.17) mg/dL and 12.73 (IQR, 7.21-17.59) mg/dL, respectively (P < .0001). One patient died during the follow-up period in group 1, as against 37 patients in group 2 (P < .0001). The median length of hospital stay in groups 1 and 2 was 6 (IQR, 4-9) days and 13 (IQR, days, respectively (P < .0001). The demographic characteristics and laboratory results of patients in the two groups are summarised in Table 1 . There was no significant difference between male and female patients with respect to TSH, FT4, FT3, anti-TPO, and anti-Tg levels. Furthermore, none of these laboratory indices showed any correlation with age. There was no significant difference between groups 1 and 2 with respect to the TSH level (P > .05). However, FT4 and Anti-Tg level, which was examined in terms of thyroid autoantibodies, was not different between the two groups; however, the anti-TPO level in group 2 was significantly higher than that in group 1 (P = .009). Thyroid nodules were detected in 9 patients (7%) in group 1 as against 32 (26%) patients in group 2 (P < .0001). Overt thyroid disorder was observed in 13 patients in this study; these included 2 patients (both with overt thyrotoxicosis) in group 1 and 11 patients (3 with overt hypothyroidism and 8 with overt thyrotoxicosis) in group 2. Subclinical thyroid disorder was observed in sx patients (all with subclinical thyrotoxicosis) in group 1 and eight patients (one subclinical hypothyroidism, seven subclinical thyrotoxicosis) in group 2. While thyrotoxicosis was more common in ICU patients, the between-group difference in this respect was not statistically significant (P > .05). Thyroid ultrasonography was performed in patients (n = 23) with thyrotoxicosis. Thyroid nodules were detected in 15 patients with thyrotoxicosis (eight with overt thyrotoxicosis and seven with subclinical thyrotoxicosis). Subacute thyroiditis was not detected in any of the patients with thyrotoxicosis. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; MCV, mean corpuscular volume; RT-PCR, real-time reverse-transcriptase polymerase chain reaction. The bold value indicates statistically significant. None of the patients in group 1 had hypothyroidism; however, hypothyroidism was observed in four (3%) patients in group 2. Of these, three patients had overt hypothyroidism, while one patient had subclinical hypothyroidism. Central hypothyroidism was not detected in any of the patients included in the study. Anti-TPO and anti-Tg levels of the patients with overt hypothyroidism in group 2 were ≥3 times higher than the normal range and were consistent with autoimmune thyroiditis. The number of patients with euthyroidism in groups 1 and 2 was 107 (86%) and 84 (67%), respectively (P = .001). The number of patients with NTIS in groups 1 and 2 was 10 (8%) and 22 (18%), respectively (P = .023). Table 3 . The majority of COVID-19 patients included in our study were men. The median age of non-ICU patients was significantly lower than that of ICU patients. The median age of patients who died in the ICU was higher than that of survivours. Studies have shown that advanced age and male sex are risk factors for COVID-19. 4, 5 The disease severity and the associated mortality increases with increase in age. In a meta-analysis of 24 observational studies (combined n = 10,150), the ICU mortality rate was found to be 41.6 (34.0-49.7) %. 6 In a retrospective study conducted in Italy (n = 1591), the mortality rate in ICU patients was found to be 26%. 7 In our study, the mortality rate in the ICU (29.6%) was slightly lower as not all patients in the ICU were included in the study owing to the study protocol. In patients with acute illness, hyperglycemia can be assumed to be an adaptive response that increases the patient's chances of sur- shown a strong association between stress hyperglycemia and adverse clinical outcomes, including mortality, morbidity, length of hospital stay, infections, and general complications. [8] [9] [10] In this study, patients with diabetes were excluded; the early morning glucose Considering that SARS-CoV-2 can induce organ damage through autoimmunity, 17 there is a distinct possibility of the occurrence of autoimmune thyroid disorders. In this study, we found no significant difference in anti-Tg levels between patients in various groups and subgroups. Anti-TPO level in ICU patients was significantly higher than that in non-ICU patients. Three of the four hypothyroid patients seen in ICU were cases of overt autoimmune hypothyroidism. Abbreviations: TSH, Thyroid-stimulating hormone, FT4, free T4, FT3, free T3, Anti-TPO, Anti-thyroid peroxidase, Anti-Tg, Anti-thyroglobulin. Anti-thyroid antibodies detected in patients may be pre-existing antibodies. However, we can state that thyroid antibodies were occurred due to COVID-19, because patients with pre-existing autoimmune thyroid diseases were not taken into the study. However, there was no significant difference in anti-TPO level between survivour and deceased subgroups of ICU patients. The high level of anti-TPO in the ICU may be due to the cytokine storm triggering autoimmunity due to COVID-19. In our study, we found no significant difference in TSH levels between various groups and subgroups; however, FT4 and FT3 levels were significantly different between ICU and non-ICU patients, and between the survivours and the deceased subgroups of ICU patients. In a study of 162 patients admitted to the ICU, FT3 levels were found to be associated with poor outcomes. 18 In another study of 116 critically ill patients without thyroid disease, only FT3 level showed a correlation with disease severity and was found to be an independent predictor of outcomes. 19 In our study, FT4 level showed no correlation with the CRP level, while the FT3 level showed a negative correlation with the CRP level. The observed negative correlation of FT3 with the length of hospital stay was consistent with the results of other studies; thus, the FT3 level may be a prognostic marker that reflects the severity of COVID-19. Low thyroid hormone levels can be observed in non-thyroidal systemic diseases, especially in critically ill patients admitted to the ICU. This phenomenon, also referred to as NTIS, is a potential protective mechanism against excessive tissue catabolism in severely ill patients. 20 The typical hormonal profile in these patients is low or low-normal serum total T4, low T3 concentration, and low, lownormal, or normal TSH. 21, 22 In a meta-analysis of 23 studies of patients with ischemic heart disease (combined n = 19 310), NTIS was associated with higher risk of all-cause mortality (hazard ratio = 2.61; 95% confidence interval = 1.89-3.59). 23 In our study, there was a higher prevalence of NTIS in ICU patients. In this study, 24% of patients who died had NTIS. In conclusion, NTIS is a clinical syndrome associated with poor prognosis in COVID-19. In the THYROCOV study conducted in Italy (n = 287), the frequency of thyrotoxicosis and hypothyroidism in non-ICU COVID-19 patients was 20.2% and 5.2%, respectively. 24 In our total study pop- Figure 4 . In addition, both thyrotoxicosis and nodules were detected in 15 patients (eight with overt thyrotoxicosis, seven with subclinical thyrotoxicosis). In our study, thyroid nodules were found to be associated with poor clinical outcomes, as they aggravate hypoxia due to compression effect and cause thyrotoxicosis. Some limitations of this study should be considered, while inter- Larger multi-centre studies are required to provide more definitive evidence. In this study, COVID-19 was found to affect thyroid hormone metabolism. Thyroid hormone disorders may worsen the cardiovascular status. Therefore, rapid evaluation of free thyroid hormones and TSH at admission will facilitate early diagnosis and appropriate treatment. Low FT3 level at admission is another risk factor for severe cases and indicates a poor prognosis. Thyroid nodules may be amongst the comorbidities that pose a risk for COVID-19, since thyroid nodules can cause tracheal compression and the nodules may cause thyrotoxicosis. The authors thank the nurses and healthcare professionals working in the Intensive Care Unit of Şırnak State Hospital for their contributions. There are no conflicts of interest. https://orcid.org/0000-0002-0752-8815 Hamza Gültekin https://orcid.org/0000-0001-9394-4999 Director-General's remarks at the media briefing on 2019-nCoV Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area COVID-19 experience of the major pandemic response center in the capital: results of the pandemic's first month in Turkey Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region Association between intensive care unit-acquired dysglycemia and in-hospital mortality Stress hyperglycemia Intensive versus conventional glucose control in critically ill patients Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Pathology of the thyroid in severe acute respiratory syndrome Covid-19 and autoimmunity Low free T 3 is associated with worse outcomes in patients in the ICU requiring invasive mechanical ventilation Do thyroid function tests independently predict survival in the critically ill? Thyroid function in critically ill patients Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness Euthyroid sick syndrome: is it a misnomer? Nonthyroidal ıllness syndrome and hypothyroidism in ıschemic heart disease population: a systematic review and meta-analysis Thyrotoxicosis in patients with COVID-19: the THYRCOV study Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees Incidental thyroid nodules on thoracic contrast-enhanced computed tomography in clinical practice during a 10-year period: Characteristics, clinical outcomes, and factors contributing to further evaluation The prognostic impact of thyroid disorders on the clinical severity of COVID-19: Results of single-centre pandemic hospital